Antipsychotics and COVID-19: the debate goes on - Authors' reply
- PMID: 34801117
- PMCID: PMC8601685
- DOI: 10.1016/S2215-0366(21)00428-4
Antipsychotics and COVID-19: the debate goes on - Authors' reply
Conflict of interest statement
LDP reports grants from Boehringer-Ingelheim and Janssen, outside the submitted work. LDP and BV are members of the ECNP ImmunoPsychiatry Network. MGM declares no competing interests.
Comment on
-
Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis.Lancet Psychiatry. 2021 Sep;8(9):797-812. doi: 10.1016/S2215-0366(21)00232-7. Epub 2021 Jul 17. Lancet Psychiatry. 2021. PMID: 34274033 Free PMC article.
-
Antipsychotics and COVID-19: the debate goes on.Lancet Psychiatry. 2021 Dec;8(12):1030. doi: 10.1016/S2215-0366(21)00396-5. Lancet Psychiatry. 2021. PMID: 34801118 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical